EVIO Inc. Executes Letter of Intent to sell C3 Labs, LLC to Digipath, Inc.
07 Dezember 2021 - 2:50PM
InvestorsHub NewsWire
Henderson, NV -- December 7, 2021 --
InvestorsHub NewsWire -- EVIO, Inc. announced today that it
intends to sell its ownership in C3 Labs, LLC dba Steep Hill CA to
Digipath, Inc. (OTCQB:DIGP) in exchange for assumption of debt and
stock in Digipath.
This sale marks the company’s next step towards
EVIO’s restructuring plans which began in January 2021. The
sale of C3 Labs means that the company will be able to divest over
$2 million in debt and future lease obligations and gain a yet to
be disclosed equity stake in Digipath.
Interim CEO Lori Glauser says “This sale gives
C3 Labs the investment it needs to achieve profitability without
EVIO taking on more debt. It also gives EVIO an investment stake in
the growing lab company while substantially reducing operating
costs.”
EVIO continues to operate its labs in Canada
and Oregon. Furthermore, the company is planning a roll-out its
blockchain technology offerings during first quarter
2022.
About
EVIO
EVIO,
Inc. is a provider of ancillary services including consulting,
R&D and analytical testing for cannabis, hemp, and
pharmaceutical companies.
For more
information, visit www.eviolabs.com
and
www.digipath.com
Safe Harbor Statement
Any statements in this press
release that are not statements of historical fact may be
considered forward-looking statements pertaining to anticipated or
projected plans, performance, and developments, as well as other
statements relating to future operations and results. Words such as
"may," "will," "expect," "believe," "anticipate," "estimate,"
"intends," "goal," "objective," "seek," "attempt," or variations of
these or similar words, identify forward-looking statements. These
forward-looking statements by their nature are estimates of future
results only, and involve substantial risks and uncertainties,
including but not limited to risks associated with the uncertainty
of future financial results, additional financing requirements,
development of new products, the Company's ability to complete
product testing and launch product commercially, the acceptance of
product in the marketplace, the uncertainty of the laws and
regulations relating to cannabis, the impact of competitive
products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed from time to time in
Company reports filed with the Securities and Exchange Commission
and OTC Markets, available at www.sec.gov or www.eviolabs.com.
For Further Information
contact:
Lori Glauser,
Interim CEO
info@eviolabs.com
EVIO (CE) (USOTC:EVIO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
EVIO (CE) (USOTC:EVIO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über EVIO Inc (CE) (OTCMarkets): 0 Nachrichtenartikel
Weitere EVIO Inc (PK) News-Artikel